



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John C. Salerno

Application No.: 10/712,806 Group Art Unit: 1646

Filed: November 13, 2003 Examiner: Not Assigned

Confirmation No.: 7854

Title: Methods of Generating Chimera

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
6-18-04	Hollie Wakefield
Date	Signature
Hollie Wakefield	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
 - ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
 - ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statement Under 37 CFR 1.97(c)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

(Applies to original applications (other than design) filed on or after May 29, 2000)

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in -§ 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.
[The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

The Examiner is requested to return a copy of the list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account ☐ in the amount of [\$]. A copy of this Statement is enclosed.
- ☐ Please charge any deficiency in fees and credit any overpayment to Deposit Account 502807.

Respectfully submitted,

ELMORE CRAIG, P.C.

By 

Carolyn S. Elmore

Registration No.: 37,567

Telephone: (978) 251-3509

Facsimile: (978) 251-3973

N. Chelmsford, MA 01863

Dated: 

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

March 1, 2004

(Use several sheets if necessary)

JUN 21 2004

ATTORNEY DOCKET NO.
3230.3000 US1

APPLICATION NO.
10/712,806

APPLICANT
John C. Salerno

FILING DATE
November 13, 2003

CONFIRMATION NO.
7854

GROUP
1646

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AA	6,303,290 B1	16 Oct 2001	Liu <i>et al.</i>
	AB	6,051,380	18 Apr 2000	Sosnowski <i>et al.</i>
	AC	5,854,030	29 Dec 1998	Dordick <i>et al.</i>
	AD	5,824,526	20 Oct 1998	Avnir <i>et al.</i>
	AE	5,618,933	08 Apr 1997	Dordick <i>et al.</i>
	AF	5,474,915	12 Dec 1995	Dordick <i>et al.</i>
	AG	5,200,334	06 Apr 1993	Dunn <i>et al.</i>
	AH	3,650,900	21 Mar 1972	Levin <i>et al.</i>
	AA2	2002/0028506 A1	07 Mar 2002	Ho <i>et al.</i>
	AB2	2002/0020931 A1	21 Feb 2002	Stowell <i>et al.</i>
	AC2	2002/0015952 A1	07 Feb 2002	Anderson <i>et al.</i>
	AD2	2001/0055797 A1	27 Dec 2001	Conroy <i>et al.</i>
	AE2			
	AF2			
	AG2			
	AH2			
	AA3			
	AB3			
	AC3			
	AD3			
	AE3			
	AF3			
	AG3			

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3230.3000 US1		APPLICATION NO. 10/712,806	
	APPLICANT John C. Salerno			
	FILING DATE November 13, 2003	CONFIRMATION NO. 7854	GROUP 1646	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
	AL	WO 00/54882	21 Sep 2000	PCT		
	AM	WO 00/54882 A1	21 Sep 2000	PCT		
	AN	WO 03/038131 A1	08 May 2003	PCT		
	AQ					
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					

EXAMINER	DATE CONSIDERED
-----------------	------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3230.3000 US1		APPLICATION NO. 10/712,806	
	APPLICANT John C. Salerno			
	FILING DATE November 13, 2003		CONFIRMATION NO. 7854	GROUP 1646

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AR	Chauret, N. <i>et al.</i> , "Description of a 96-well plate assay to measure cytochromes p4503 A inhibition in human liver microsomes using a selective fluorescent probe," <i>Anal. Biochem.</i> 276 :215-226 (1999).
	AS	Crespi, C.L. <i>et al.</i> , "Microtiter plate assays for inhibition of human, drug-metabolism cytochromes P450," <i>Anal. Biochem.</i> , 248 :188-190 (1997).
	AT	Gill, I. <i>et al.</i> , "Encapsulation of biologicals within silicate, siloxane, and hybrid sol-gel polymers: an efficient and generic approach," <i>J. Am. Chem. Soc.</i> , 120 (34):8587-8598 (1998).
	AU	Gill, I. <i>et al.</i> , "Bioencapsulation within synthetic polymers (Part 1): sol-gel encapsulated biologicals," <i>TIBTECH</i> , 18 :282-296 (2000).
	AV	Iwatsubo, T. <i>et al.</i> , "Prediction of <i>in vivo</i> drug metabolism in the human liver from <i>in vitro</i> metabolism data," <i>Pharmacol. Ther.</i> , 73 :147-171 (1997).
	AW	Kim, Y. <i>et al.</i> , "Stable sol-gel microstructured and microfluidic networks for protein patterning," <i>Biotechnology & Bioengineering</i> , 73 (5): 331-337 (2001).
	AX	Kim, J. <i>et al.</i> , "Protease-containing silicates as active antifouling materials," <i>Biotechnology Prog.</i> , 18 (3):551-555 (2002).
	AY	Lake, B.G. <i>et al.</i> , "Induction of CYP3A Isoforms in cultured precision-cut human liver slices," <i>Xenobiotica</i> , 27 :1165-1173 (1997).
	AZ	Nagy, G. <i>et al.</i> , "Amperometric microcell for enzyme activity measurements," <i>Analytical Chemistry</i> , 70 (10):2156-2162 (1998).
	AR2	Novick, S.J. <i>et al.</i> , "Preparation of active and stable biocatalytic hydrogels for use in selective transformations," <i>Chemistry of Materials</i> , 10 (4):955-958 (1998).
	AS2	Novick, S.J. <i>et al.</i> , "Investigating the effects of polymer chemistry on activity of biocatalytic plastic materials," <i>Biotechnology and Bioengineering</i> , 68 (6):665-671 (2000).
	AT2	Park, C.B. <i>et al.</i> , "Sol-gel encapsulated enzyme arrays for high-throughput screening of biocatalytic activity," <i>Biotechnology & Bioengineering</i> , 78 (2):229-235 (2002).
	AU2	Sergeeva, M.V. <i>et al.</i> , "Peptide synthesis using proteases dissolved in organic solvents," <i>Enzyme Microbial. Technology</i> , 20 :623-628 (1997).
	AV2	Silber, P.M. <i>et al.</i> , "In vitro methods for predicting human toxicity," <i>Lab Animal</i> , 23 :33-37 (1994).
	AW2	Wang, P. <i>et al.</i> , "Biocatalytic plastics as active and stable materials for biotransformations," <i>Nature Biotechnology</i> , 15 :789-793 (1997).
	AX2	Zomorodi, K. <i>et al.</i> , "Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting <i>in vivo</i> hepatic clearance," <i>Xenobiotica</i> , 25 :907-916 (1995).

EXAMINER	DATE CONSIDERED
-----------------	------------------------